

Mechanism of resistance to neuraminidase inhibitors of influenza A viruses


Bruno LINA

Université Lyon 1, UMR 5537 CNRS

NRC influenza viruses, région sud,

Laboratoire de Virologie des HCL, Lyon

Schematic representation of influenza



Putative antiviral targets


Neuraminidase inhibitors

Haemagglutinin inhibitors



Ion channel (M2) blockers

Nucleoprotein inhibitors

Polymerase inhibitors



Influenza Neuraminidase Glycoprotein




Commercially available influenza virus neuraminidase inhibitors


Zanamivir (Relenza®)

Oseltamivir (Tamiflu®)


Peramivir (not shown)



Ac N neuraminique



Zanamivir



Oseltamivir


NAI Resistance : Preliminary data

Mutations associated with resistance and susceptibility to NAIs

In vitro data from LV Gubavera, Vir Res 2004 :

function	position	virus	treatment	oseltamivir	zanamivir	peramivir
Framework	N119V	H3N2	Oseltamivir	R	S	S
	H274Y	H1N1	Oseltamivir	R	S	R
		H5N1	Oseltamivir	R	S	R
	D198N	B	Oseltamivir	R	S	S
Catalytic	R292K	H3N2	Oseltamivir	R	Nd/R	nd
	R152K	B	Zanamivir	R	R	R


Resistance to neuraminidase inhibitors in influenza A



Mechanisms of Influenza virus resistance to neuraminidase inhibitors


Binding tight

Release enhance (N2)




Binding Tight or moderate

NA dependence decrease



Binding moderate

Release enhance (N2)



Fitness ++++

Resistant to inhibitor

Fitness +/-

Decrease inhibitor efficiency


Fitness ++

A H5N1 and susceptibility to NAIs


Review about level of resistance

- 1- NISM (Antivir Res, 2005) : 0,4%
- 2- Kiso et al (Lancet, 2004) : 9/50 children
- 3- Ferraris et al (Antivir Res, 2005) : 0,9%
- 4- deJong et al (NEJM, 2005) : 2 cases of A H5N1
- 5- Whitley et al (Pediatr Infect Dis, 2001) : 4% in children
- 6- Evolution of the susceptibility of A H5N1 strains
- 7- Ison et al (JID 2006) : analysis of 3 cases with resistant strains
- 8- Others...

Influenza A H5N1 as in July 2006




○ Clade 1



○ Clade 2

Phylogenetic analysis of A H5N1 Ha1



From A Hay, EISS meeting 2006, Malta

Level of susceptibility of clinical isolates

- In vitro, H5N1 isolates from poultry and humans are susceptible to both NAIs
- Viruses from the 2 clades may have different susceptibility patterns:
 - Clade 1 seems to be less susceptible to NAIs than Clade 2 viruses
 - Clade 1 is resistant to Amantadine while some Clade 2 viruses are susceptible

Level of transmissibility of resistant isolates

- Amantadine resistant isolates are highly transmissible
- 119 mutants have been shown to be transmissible in ferrets (Matrosovich et al, 2006)
- 274 mutants seem to have been transmitted from a H5N1 infected child (deJong et al, 2005)
- In highly replicating viruses such as A H5N1, fitness reduction due to NAI resistance may not impair transmissibility

NAI Resistance : recent data from the literature

Review about level of resistance

- 1- NISM (Antivir Res, 2005) : 0,4%
- 2- Kiso et al (Lancet, 2004) : 9/50 children
- 3- Ferraris et al (Antivir Res, 2005) : 0,9%
- 4- deJong et al (NEJM, 2005) : 2 cases of A H5N1
- 5- Whitley et al (Pediatr Infect Dis, 2001) : 4% in children
- 6- Evolution of the susceptibility of A H5N1 strains
- 7- Ison et al (JID 2006) : analysis of 3 cases with resistant strains
- 8- Others...

No concensus on what is the cut-off (threshold) for resistance



Impact of resistance on virus epidemiology

- 1- Reduction of virus Fitness
- 2- Reduction of virus transmission/infectivity (but...)
- 3- No transfer of resistance (N1 to N2; H1N1 to H5N1)
- 4- No cross-resistance with M2 blockers
- 5- Different level of resistance according to the substitutions (Oseltamivir vs Zanamivir; in vitro data)
- 6- Quasi-species and selection of resistance
- 7- Impact of prophylactic treatments ?
- 8- Different level of resistance depending on Na sub-type ?



Surveillance of emerging NAI-resistant H1N1 & H3N2 viruses

Fluorometric Neuraminidase Assay

❖ Neuraminidase activity assay



❖ Neuraminidase activity inhibition assay



Zanamivir
or
Oseltamivir

15 min – 37°C

MUN

2'-(4-methylumbelliferyl)- α -D-N-acetylneuraminic acid

1 H – 37°C

1 H – 37°C




Ex : 355nm


Em : 460 nm

R292K NAI profile

Neuraminidase inhibition fluorescence test
on wild type virus and R292K by **Zanamivir**



Neuraminidase inhibition fluorescence test
on wild type virus and R292K by **Oseltamivir**



IC50 nM

A/Sydney/05/97

R292K

N

Zanamivir

Mean

SD

CV

Oseltamivir

Mean

SD

CV

3.7

1.8

48.7

0.67

0.37

55.3

22.86

7.66

33.5


14914

8728


58.5

E119V NAI profile

Neuraminidase inhibition fluorescence test on B/Beijing/1/87 Wild type and R152K **mutant** virus by **Zanamivir**



Neuraminidase inhibition fluorescence test on B/Beijing/1/87 Wild type and R152K **mutant** virus by **Oseltamivir**




IC50 nM	Zanamivir				Oseltamivir			
	N	Mean	SD	CV	N	Mean	SD	CV
B/Beijing/1/87 WT	5	6.7	2.32	34.95	5	15.6	5.15	33.1
B/Beijing/1/87 R	5	6274	5363	85.5	5	438.2	83.1	19


Sensitivity of influenza viruses to zanamivir and oseltamivir

A study performed on 1180 viruses circulating in France (2002-2006) prior to and after the introduction of NAIs in clinical practice with a high throughput assay

IC50 Zanamivir



IC50 Oseltamivir



Zanamivir \downarrow **Oseltamivir** \uparrow **Susceptibility values**



	Zanamivir \downarrow IC_{50} (nM)	Oseltamivir \uparrow IC_{50} (nM)
A/H3N2	3.09	0.9
A/H1N2	6.70	2.38
A/H1N1	1.09	1.62
B	11.90	30.20

Detection of influenza virus with decreased susceptibility to neuraminidase inhibitors

1- Outliers viruses :

2- Resistant viruses :

Sensitivity of A/H3N2 influenza viruses to zanamivir and oseltamivir : 2002-2005




- ❖ H3 strains were tested with a fluorometric neuraminidase inhibition assay, underlining differences in IC₅₀ range according to the anti-neuraminidase drug
- ❖ 3 viruses were isolated with upper limit oseltamivir IC₅₀ values
- ❖ 8 viruses were isolated with upper limit zanamivir IC₅₀ values
- ❖ 7 point mutations were isolated from the neuraminidase sequence of these outliers viruses

A18S ; L23F ; C42F ; R143V ; E199K ; S332F ; K421N

NA substitutions to be analysed by Reverse Genetics

Neuraminidase mutations : association with resistance



Acknowledgements

- Olivier Ferraris
- Nicole Kessler
- Vincent Moules
- Shaker Al Farress
- Vanessa Escuret

UMR 5537 CNRS-UCBL

- Martine Valette
- Les « grogettes »

NRC

- Clémence Georges Courbot Lyon Biopole P4 Jean Mérieux
- Maude Bouscambert
- Stéphanie Mundweiller
- Emilie Frobert

- Alan Hay NIMR (UK)
- Lin Yi Pu

